poisar

Stocks · News reference

LivaNova Announces Publication of 36-Month CORE-VNS Study Results

Fiscal.ai

LivaNova PLC announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results from the CORE-VNS study, demonstrating the long-term effectiveness of VNS Therapy for drug-resistant epilepsy.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncResearchandmarkets.Com

    Global Sacral Neuromodulation Market Size, Share, Trends and Forecast 2026-2036: Rechargeable, MRI-Compatible Systems Drive 11.1% CAGR

    The global sacral neuromodulation market is estimated at USD 1.37 billion in 2026 and projected to reach USD 3.92 billion by 2036, growing at 11.1% CAGR. Market expansion is driven by rising prevalence of urinary and fecal incontinence, aging populations, and technological advancements in rechargeable and MRI-compatible devices. Key challenges include high procedural costs and complex regulatory requirements. North America leads the market while Asia-Pacific is expected to register the fastest growth.

  2. SEC EDGARSEC EDGAR

    8-K filing — LivaNova PLC (LIVN)

    Filed: 2026-11-04 AccNo: 0001639691-26-000111 Size: 905 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits